Ticker brief
INCY INCYTE CORP
Consumer, Non-cyclical · Biotechnology
last close
$116.86
1 day
+2.7%
14 days
+19.0%
mkt cap
$23.3B
signals 14d
16
authors 14d
11
Sentiment — last 14 days
daily mean sentiment, 2026-06-19 → 2026-07-02 · now +0.25 (−1 bearish … +1 bullish)
Who spoke11
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @Stockspy1 | C | +0.01 | 4 | -0.25 |
| @OzmosiHealth | C | · | 2 | +0.33 |
| @BioStocks | C | -0.39 | 2 | +0.45 |
| @t3live | C | +0.10 | 1 | +0.20 |
| @PrismMarketView | C | · | 1 | +0.15 |
| @jfahmy | C | +1.07 | 1 | +0.30 |
| @BiopharmIQ | B | · | 1 | +0.35 |
| @fj_nextstage | C | +1.07 | 1 | +0.10 |
| @RoyLMattox | C | -1.34 | 1 | +0.50 |
| @AryaFintech | C | +0.59 | 1 | +0.30 |
| @schaeffers | C | -3.72 | 1 | +0.25 |
Recent signals16of 16 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-02 | @schaeffers | +0.25 | INCY options spike on drug approvals and settlement; 7551 puts, 80x norm. | — | tweet ↗ |
| 2026-07-01 | @AryaFintech | +0.30 | Reports top 10 recommendation list returned 25.69% vs SPY 9.24%. | +2.7% | tweet ↗ |
| 2026-06-28 | @RoyLMattox | +0.50 | Targeting leading biotech names — Author says these biotech stocks are being targeted. | +2.7% | tweet ↗ |
| 2026-06-26 | @fj_nextstage | +0.10 | IBD50 ranking changes and new entries. | +2.7% | tweet ↗ |
| 2026-06-26 | @BiopharmIQ | +0.35 | Biotech open news list with price moves and discrete catalysts, capped to six tickers. | +2.7% | tweet ↗ |
| 2026-06-26 | @jfahmy | +0.30 | INCY moving to new highs with chart cited. | +2.7% | tweet ↗ |
| 2026-06-26 | @OzmosiHealth | +0.15 | Star Therapeutics data is tagged to INCY but the direct issuer relationship is unclear. | +2.7% | tweet ↗ |
| 2026-06-26 | @Stockspy1 | -0.27 | States INCY is breaking out. | +2.7% | tweet ↗ |
| 2026-06-26 | @BioStocks | +0.50 | INCY announces positive CHMP opinion for Opzelura in moderate atopic dermatitis. | +2.7% | tweet ↗ |
| 2026-06-25 | @Stockspy1 | +0.15 | Skeptical of INCY profile being hard to understand despite saying it sounds cool. | +8.7% | tweet ↗ |
| 2026-06-25 | @Stockspy1 | -0.45 | Long INCY midcap biotechnology. — Explicitly says weekly chart makes him giddy and he is long INCY. | +8.7% | tweet ↗ |
| 2026-06-25 | @PrismMarketView | +0.15 | Describes AI changing vitiligo care and tags related healthcare tickers. | +8.7% | tweet ↗ |
| 2026-06-24 | @Stockspy1 | -0.42 | Buy the rotation in INCY as breakout brews. — Calls INCY a biotech mid-cap with breakout brewing and says buy the rotation. | +7.7% | tweet ↗ |
| 2026-06-24 | @t3live | +0.20 | Premarket report with earnings, guidance, futures, commodities and movers. | +7.7% | tweet ↗ |
| 2026-06-22 | @BioStocks | +0.40 | BMO upgrades INCY to Market Perform from Underperform with $94 PT. | +12.7% | tweet ↗ |
| 2026-06-19 | @OzmosiHealth | +0.50 | Incyte Japan announces approval of Minjuvi combination therapy for DLBCL. | +19.0% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.